XPO (XPO, Inc.) Stock Analysis - AI Report

XPO, Inc. (XPO) is a publicly traded Industrials sector company. As of May 20, 2026, XPO trades at $210.00 with a market cap of $23.54B and a P/E ratio of 78.45. XPO moved +4.21% today. Year to date, XPO is +45.76%; over the trailing twelve months it is +60.95%. Its 52-week range spans $85.06 to $231.46. Analyst consensus is strong buy with an average price target of $224.75. Rallies surfaces XPO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the AI research view on XPO?

Rallies AI research for XPO combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.

XPO Key Metrics

Key financial metrics for XPO
MetricValue
Price$210.00
Market Cap$23.54B
P/E Ratio78.45
EPS$2.69
Dividend Yield0.00%
52-Week High$231.46
52-Week Low$85.06
Volume1.20M
Avg Volume0
Revenue (TTM)$8.16B
Net Income$316.00M
Gross Margin0.00%

Latest XPO News

Recent XPO Insider Trades

  • Landry Allison sold 3.25K (~$438.87K) on Sep 11, 2025.
  • Bates David J. bought 1.88K (~$199.58K) on Mar 13, 2025.

XPO Analyst Consensus

16 analysts cover XPO: 0 strong buy, 13 buy, 2 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $224.75.

Common questions about XPO

What is the AI research view on XPO?
Rallies AI research for XPO combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for XPO?
Rallies AI research for XPO combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is XPO research on Rallies investment advice?
No. Rallies provides research, data, and educational context for XPO. It does not provide personalized investment advice.
XPO

XPO